Allergy Therapeutics plc
LSE AGY.L
Allergy Therapeutics plc Price to Sales Ratio (P/S) on January 14, 2025: 6.28
-
Allergy Therapeutics plc 52-week high Price to Sales Ratio (P/S) is 6.37 on January 06, 2025, which is 1.44% above the current Price to Sales Ratio (P/S).
-
Allergy Therapeutics plc 52-week low Price to Sales Ratio (P/S) is 0.02 on January 16, 2024, which is -99.68% below the current Price to Sales Ratio (P/S).
-
Allergy Therapeutics plc average Price to Sales Ratio (P/S) for the last 52 weeks is 3.60.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Manuel Llobet |
| IPO Date | Oct. 11, 2004 |
| Location | United Kingdom |
| Headquarters | Dominion Way |
| Employees | 612 |
| Sector | Health Care |
| Industries | |
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email